Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.
about
Pitavastatin in cardiometabolic disease: therapeutic profileStatins in cardiometabolic disease: what makes pitavastatin different?Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseOmega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemiaLive Probiotic Lactobacillus johnsonii BS15 Promotes Growth Performance and Lowers Fat Deposition by Improving Lipid Metabolism, Intestinal Development, and Gut Microflora in Broilers.Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression.The impact of a disease management program (COACH) on the attainment of better cardiovascular risk control in dyslipidaemic patients at primary care centres (The DISSEMINATE Study): a randomised controlled trial.Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.The LDL-HDL profile determines the risk of atherosclerosis: a mathematical model.Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia.Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.Current Perspectives on rosuvastatin.Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acidsThe therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes.High density lipoprotein: a therapeutic target in type 2 diabetes.Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients.Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trialEmerging options in the treatment of dyslipidemias: a bright future?Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.The effects of statin medications on aerobic exercise capacity and training adaptations.Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatmentLipids and cardiovascular disease: where does dietary intervention sit alongside statin therapy?Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes.ProAlgaZyme subfraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites.Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.Familial aggregation of metabolic syndrome indicators in Portuguese families.Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.The causes and consequences of low levels of high density lipoproteins in patients with diabetes.The Effect of Testosterone on Cardiovacular Biomarkers in the Testosterone Trials.Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
P2860
Q21246037-53A23872-F35A-4360-8BB5-07D12D4D1D1BQ27010638-FBBBA9D7-7ECE-43C4-9B7B-CEE93F315120Q28075372-867F3F36-5E4C-4837-AC17-B6FA7AC4EB8FQ28076399-9FCC0B05-55AF-466B-91BB-AC82FF608E3BQ33785678-FD64A1BD-4AEE-4757-AE2F-83210B1ACE7AQ34075414-B86E0BEB-8805-4274-A607-0EB5BC748A23Q34076242-2984DD73-2113-43B9-83A0-16DFD11AA337Q34437027-3FC0393E-804D-42A6-A9CF-404F45D4C4CFQ35088129-F384BBDF-89B6-4780-AD07-58C987429E56Q35118830-BC7DC21A-3A1B-4514-A65C-4111DB948A40Q36139098-E87F0E74-8703-4EE0-8133-4DFAC2681A90Q36152978-54DE8077-2116-4B32-A09C-F34D6EA0946BQ36199734-32E50710-6EB3-402E-A1B1-96C90125C3D6Q36307308-3E634140-AD7D-4257-AF16-31901F267ADEQ36419283-BDDEDC0A-5331-40AC-83D9-49F6A72CA6E7Q36599589-CD9324FA-983B-4134-81BF-D2E0A21261D0Q36796490-88D1DA7A-30EE-46A0-89F8-AF9A00B7CFA3Q37195954-47F2DB5D-ECC5-4AFF-9A8C-5C1DF712BF09Q37211868-D6AE94D4-4FD0-49E1-B5D6-F45EA4E51A10Q37264429-40AD5325-1A2A-4A47-8406-E808FE63B013Q37551536-5BAB94EA-C352-4FB6-BFA3-87CCADF3A624Q37644907-B73EEFDE-0311-4DB5-A5AB-1DC78F4B75B5Q37695401-500CA54C-9F85-47C0-B0BF-B1A723AD9F11Q37700760-9F28F874-1CF7-4B05-8514-051895A6914CQ37842462-2EFF7759-7359-440A-A651-E8019DCCB0FFQ37953462-C746D025-E71F-48E1-9A76-78AE840F2888Q38104228-3823CE02-0755-4F15-A728-5AF696E18298Q38228143-2AF5C5F1-178E-472C-9366-6A27AAF8FFCBQ38431166-43CDECC4-1473-492F-B47E-9CD751B04090Q38757894-542F734A-5CCF-4734-9125-0561322E4EF1Q38816273-85583021-E463-48C9-8931-FF4326FE7539Q39424127-99564B57-5EE9-44DA-9A2E-7BDC2979DBE3Q39717289-9E7F2067-FB51-42EA-BA63-67221BB8CDCDQ41856694-709A7DFB-1CE5-460A-A7B6-4556E2232083Q41921823-F2B7EABB-5CEC-4CD1-8FAE-89BA7E3462A6Q42655863-466FCEEE-59A6-488F-A7DA-60E890C849A7Q42725914-AEA7FE89-2C34-4F27-958E-7A1F399D202AQ42773416-F30E124E-CB82-4BD7-95B2-0CB9F5D1DCAEQ47281332-048F7240-6390-4D03-B459-5D1AA0698BAFQ48311790-9EF315A4-483F-47B2-97FF-4AA7B7E6F118
P2860
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@ast
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@en
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@nl
type
label
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@ast
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@en
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@nl
prefLabel
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@ast
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@en
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@nl
P2093
P2860
P356
P1476
Effect of statins on HDL-C: a ...... lysis of the VOYAGER Database.
@en
P2093
Gunnar Brandrup-Wognsen
Mike K Palmer
Philip J Barter
Stephen J Nicholls
P2860
P304
P356
10.1194/JLR.P002816
P577
2009-12-02T00:00:00Z